Abstract
Thrombosis plays a central role in the pathogenesis of acute coronary syndromes. Currently available therapies, which possess primarily antithrombotic and fibrinolytic properties, have improved the clinical outcome of patients with unstable angina and myocardial infarction. However, because of residual thrombosis, a significant proportion of patients with acute coronary syndromes develop complications such as reocclusion, reinfarction, recurrent ischemia, and stenosis, with clinical manisfestations ranging from stable angina to death. We currently lack critical information regarding the balance between thrombosis and fibrinolysis that would help guide the development of short-term, long-term, and preventive treatments. Plasma markers of thrombosis and fibrinolysis are likely to be crucial to the development and use of current and future therapeutic approaches. The following is an overview of some currently available and novel assays for thrombotic and fibrinolytic activity, and recent clinical data on their potential role in the assessment of acute coronary syndromes and in guiding therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bach RR. Initiation of coagulation by tissue factor. CRC Crit Rev Biochem 23:339, 1988.
Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol 134:1087, 1989.
Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 86:2839, 1989.
Annex BH, Denning SM, Channon KM, Skerch MH Jr, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 91:619, 1995.
Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Medlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 91:2253, 1993.
Taubman MB. Tissue factor regulation in vascular smoorh muscle: A summary of studies performed using in vivo and in vitro models. Am J Cardiol 72:55C, 1993.
Albrecht S, Luther T, Grossman H, Flossel C, Korzsch M, Muller M. An ELISA for tissue factor using monoclonal antibodies. Blood Coagul Fibrinolysis 3:263, 1992.
Takahashi H, Satoh N, Wada K, Takakuwa E, Seki Y, Shibata A. Tissue factor in plasma of patients with disseminated intravascular coagulation. Am J Hematol 46:333, 1994.
Koyama T, Nishida K, Ohdama S, Sawada M, Murakami N, Hirosawa S, Kuriyama R, Matsuzawa K, Hasegawa R, Aoki N. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 87:343, 1994.
Fukada S, Iijima K, Nakamura K. Measuring tissue factor (factor III) activity in plasma. Clin Chem 35:1897, 1989.
Iijima K, Fukuda C, Nakamura K. Measurements of tissue factor-like activity in plasma of patients with DIC. Thromb Res 61:29, 1991.
Francis JL, Carvalho M, Francis DA. The clinical value of tissue factor assays. Blood Coagul Fibrinolysis 6:S37, 1995.
Leatham EW, Bath PMW, Tooze JA, Camm AJ. Increased monocyre tissue factor expression in coronary disease. Br Heart J 73:10, 1995.
Serneri GGN, Abbate R, Gori AM, Attanasio M, Martini F, Giusti B, Dabizzi P, Poggesi L, Modesti PA, Trotta F, Rostagno C, Boddi M, Gensini GF. Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation 86:790, 1992.
Jude B, Agraou B, McFadden EP, Susen S, Bauters C, Lepelley P, Vanhaesbroucke C, Devos P, Cosson A, Asseman P. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. Circularion 90:1662, 1994.
Edwards RL, Silver J, Rickles FR. Human tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haemost 69:205, 1993.
Andoh K, Kubota T, Takada M, Tanaka H, Kobayashi N, Maekawa T. Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation. Cancer 59:748, 1987.
Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity. Proc Natl Acad Sci USA 83:3460, 1986.
Archipoff G, Beretz A, Freyssinet J, Klein-Soyer C, Brisson C, Cazenave JP. Heterogeneous regulation of constitutive thrombomodulin or inducible tissue factor activities on the surface of human saphenous vein endothelial cells in culture following stimulation by interleukin-1, tumor necrosis factor, thrombin or phorbol ester. Biochem J 273:679, 1991.
Wada H, Wakita Y, Shiku H. Tissue factor expression in endothelial cells in health and disease. Blood Coagul Fibrinolysis 6:S26, 1995.
Nakagaki T, Fosrer DC, Berkner KL, Kisiel W. Initiation of the extrinsic pathway of blood coagulation: Evidence for the factor dependent autoactivation of human coagulation factor VII. Biochemistry 30:10819, 1991.
Seligsohn U, Casper CK, Osterud B, Rapaport SI. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 53:828, 1979.
Nemerson Y, Repke D. Tissue factor accelerates the activation of coagulation factor VII: The role of a bifunctional coagulation cofactor. Thromb Res 40:351, 1985.
Nemerson Y, Esnouf MP. Activation of a proteolytic system by a membrane lipoprotein: Mechanism of action of tissue factor. Proc Natl Acad Sci USA 70:310, 1973.
Seligsohn U, Osterud B, Rapaport SI. Coupled amidolytic assay for factor VII: Its use with a clotting assay to determine the activity state of factor VII. Blood 52:978, 1978.
Morrissey J. Tissue factor interactions with factor VII: Measurement and clinical significance of factor VIIa in plasma. Blood Coagul Fibrinolysis 6:S14, 1995.
Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activation factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81:734, 1993.
Hultin MB. Fibrinogen and factor VII as risk factors in vascular disease. Prog Hemost Thromb 10:215, 1991.
Broze GJ, Hickman S, Miletich JP. Monoclonal antihuman factor VII antibodies. Detection in plasma of a second protein antigenically and genetically related to factor VII. J Clin Invest 76:937, 1985.
Takase T, Tuddenham E, Chand S, Goodall AH. Monoclonal antibodies to human factor VII: A one step immunoradiometric assay for VII:Ag. J Clin Pathol 41:337, 1988.
Bom VJJ, van Tilburg NH, Krommenhoek-van Es C, Bertina RM. Immunoradiometric assays for human coagulation factor VII using polyclonal antibodies against the Ca(II)-dependent and Ca(II)-independent conformation. Thromb Haemost 56:343, 1986.
Kitchen S, Malia RG, Preston FE. A comparison of methods for the measurement of activated factor VII. Thromb Haemost 68:301, 1992.
Mann KG. Factor VII assays, plasma triglyceride levels, and cardiovascular disease risk. Arteriosclerosis 9:783, 1989.
Waxman E, Ross JB, Laue TM, Guha A, Thiruvikraman SV, Lin TC, Konigsberg WH, Nemerson Y. Tissue factor and its extracellular soluble domain. The relationship between intermolecular association with factor VIIa and enzymatic activity of the complex. Biochemistry 31:3998, 1992.
Waxman E, Laws WR, Laue TM, Yale N, Ross JBA. Human factor VIIa and its complex with soluble tissue factor: Evaluation of asymmetry and conformational dynamics by ultracentrifugation and fluorescence anisotropy decay methods. Biochemistry 32:3005, 1993.
Paborsky LR, Caras IW, Fisher KL, Gorman CM. Lipid association, but not the transmembrane domain, is required for tissue factor activity. Substitution of the transmembrane domain with a phosphatidylinositol anchor. J Biol Chem 32:3005, 1991.
Neuenschwander PF, Morrissey JH. Deletion of the membrane-anchoring region of tissue factor abolishes autoactivation of factor VII, but not cofactor function: Analysis of a mutant with a selective deficiency in activity. J Biol Chem 267:14477, 1992.
Kario K, Sakata T, Matsuo T, Miyata T. Factor VII in non-insulin-dependent diabetic patients with microalbuminuria. Lancet 342:1552, 1993.
Kario K, Miyata T, Sakata T, Matsuo T, Kato H. Fluorogenic assay of activated factor VII: Plasma factor VIIa levels in relation to arterial vascular diseases in Japanese. Arterioscler Thromb 14:265, 1994.
Rugman FP, Jenkins JA, Daguid JK, Maggs PB, Hay CRM. Prothrombin fragment F1+2: Correlations with cardiovascular risk factors. Blood Coagul Fibrinolysis 5:335, 1994.
Meade TW, Brozovic M, Chakrabarti RA, Haines AP, Imeson JD, Mellows S, Millet GJ, North WRS, Stirling Y, Thompson SG. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 2:533, 1986.
Balleisen L, Schulte H, Assmann G, Epping PH, Loo JVD. Coagulation factors and the progress of coronary heart disease. Lancet 2:461, 1987.
Hoffman C, Shah A, Sodums M, Hultin MB. Factor VII activity state in coronary artery disease. J Lab Clin Med 111:475, 1988.
Carvalho de Sousa J, Azevedo J, Soria C, Barros F, Ribeiro C, Parreira F, Caens JP. Factor VII hyperactivity in acute myocardial thrombosis: A relation to the coagulation activation. Thromb Res 51:165, 1988.
Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, Gaetano GD, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Volpe AD, Polli E, for The PLAT Study Group. The PLAT study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients — principal results. Arterioscler Thromb 12:1063, 1992.
Heinrich J, Balleisen L, Schulre H, Assmann G, Loo JVD. Fibrinogen and factor VII in the prediction of coronary risk: Results from the PROCAM study in healthy men. Arterioscler Thromb 14:54, 1994.
Ruddock V, Meade TW. Factor-VII activity and ischaemic heart disease: Fatal and non-fatal events. Q J Med 87:403, 1994.
Miller G, Stirling Y, Esnouf MP, Heinrich J, Loo JVD, Kienast J, Wu KK, Morrissey JH, Meade TW, Martin JC, Imeson JD, Cooper JA, Finch A. Factor Vil-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bioassay to activated factor VII: An international study. Thromb Haemost 71:38, 1994.
Broze GJ, Girard TJ, Novotony WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 29:7539, 1990.
Rappaport SI. The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation. Thromb Haemost 66:6, 1991.
Novotny WF, Girard TJ, Miletich JP, Broze GJ. Platelets secrete a coagulation inhibitor functionally and antigenically similar ro the lipoprorein associated coagulation inhibitor. Blood 72:2020, 1988.
Erhardtsen E, Ezban M, Madsen MT, Diness V, Glazer S, Hedner U, Nordfang O. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 6:388, 1995.
Lindahl AK, Odegaard OR, Sandset PM, Harbitz TB. Coagulation inhibition and activation in pancreatic cancer: Changes during progress of disease. Cancer 70:2067, 1992.
Sandset PM, Lund H, Norseth J, Abilgaard U, Ose L. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb 11:138, 1991.
Hansen JB, Olsen JO, Osterud B. Physical exercise enhances plasma levels of extrinsic pathway inhibitor. Thromb Haemost 64:124, 1990.
Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 78:387, 1991.
Warr TA, Rao LV, Rapaport SI. Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepato-cellular disease. Blood 74:994, 1989.
Sabharwal AK, Ameri A, Bajaj M, Hyers TM, Tricomi SM, Taylor FB, Bajaj SP. Tissue factor pathway inhibitor levels in plasma and lavage fluids in acute lung injury. Am Rev Respir Dis 145:453a, 1992.
Sandset PM, Sirnes PA, Abilgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br J Haematol 72:391, 1989.
Moore E, Hamsten A, Karpe F, Bavenholm P, Blomback M, Silveria A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemost 71:707, 1994.
Hansen JB, Huseby KR, Huseby NE, Sandset PM, Hanssen TA, Nordoy A. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 15:879, 1995.
Sandset PM, Abilgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50:803, 1988.
Valentin S, Ostergaard P, Kristensen H, Nordfang O. Simultaneous presence of tissue factor pathway inhibitor (TFPI) and low molecular weight heparin has a synergistic effect in different coagulation assays. Blood Coagul Fibrinolysis 2:692, 1991.
Hoppensteadt DA, Jeske W, Fareed J, Bermes EWJ. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 6:S57, 1995.
Broze GJ. Tissue factor pathway inhibitor and the revised theory of coagulation. Ann Rev Med 46:103, 1995.
Anderson S, Cohen AT, Melissari E, Scully MS, Kakkar VV. Loss of heparin-releasable tissue factor pathway inhibitor in patients undergoing PTCA. Thromb Haemost 73:324, 1995.
Kijowski R, Hoppensteadt D, Walenga J, Borris L, Lassen NR, Fareed J. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis (DVT) prophylaxis in patients treated with low molecular weight heparin. Thromb Res 74:53, 1994.
Jeske W, Hoppensteadt D, Klauser R, Kammereit A, Eckenberger P, Haas S, Wyld P, Fareed J. Effect of repeated aprosulate and enoxaparin administration on tissue factor pathway inhibitor antigen levels. Blood Coagul Fibrinolysis 6:119, 1995.
Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2 fragment and thrombin-antithrombin complex. Blood 59:1086, 1983.
Miletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on platelets. J Biol Chem 253:6908, 1978.
Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S.Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 76:1, 1990.
Bauer KA, Rosenberg RD. Activation markers of coagulation. Bailliere’s Clin Haematol 7:523, 1994.
Lau HK, Rosenberg JS, Beeler DL, Rosenberg RD. The isolation and characterization of a specific antibody population directed against the prothrombin activation fragments F2 and F1+2. J Biol Chem 254:8751, 1979.
Tripoldi A, Chantarngkul V, Bottasso B, Mannucci PM. Poor comparability of prothrombin fragment 1 + 2 values measured by two commercial ELISA methods: Influence of different anticoagulants and standards. Thromb Haemost 71:605, 1994.
Boneu B, Bes G, Pelzer H, Sie P, Boccalon H. D-dimer, thrombin antithrombin III complexes, and prothrombin fagments 1 + 2: Diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 65:28, 1991.
Boisclair MD, Ireland H, Lane DA. Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev 4:25, 1990.
Kienast J, Thompson SG, Raskino C, Pelzer H, Fechtrup C, Ostermann H, Loo JVD. Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: Relation to the presence and severity of coronary atherosclerosis. Thromb Haemost 70:550, 1993.
Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90:61, 1994.
Bruhn HD, Liebsch J, Wagner C. Documentation of hypocoagulability by measurement of prothrombin fragment F1+2 when introducing oral anticoagulant therapy. Thromb Res 68:317, 1992.
Estivals M, Pelzer H, Sie P, Pichon J, Boccalon H, Boneu B. Prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: Effects of heparin treatment. Br J Haematol 78:421, 1991.
Slaughter TF. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 80:520, 1994.
Smith RC, Leung JM, Mangano DT, The SPI Research Group. Postoperative myocardial ischemia in patients undergoing coronary artery bypass graft surgery. Anesthesiology 74:464, 1991.
Bauer KA, Rosenberg RD. The parhophysiology of the prechrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 70:343, 1987.
Li Z, Wu J, Mammen EF. Prothrombin fragment F1+2 and oral anticoagulant therapy. Thromb Res 75:601, 1994.
Hafner G, Swars H, Erbel R, Ehrenthal W, Rupprecht HJ, Lotz J, Meyer J, Prellwitz W. Monitoring prothrombin fragment 1 + 2 during initiation of oral anticoagulant therapy after intercoronary stencing. Ann Hematol 65:83, 1992.
van den Bos AA, Deckers JW, Heyndrickx GR, Laarman GJ, Suryapranata H, Zijlstra F, Close P, Rijnierse JJMM, Buller HR, Serruys PW.Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 88:2058, 1993.
Kaiser B, Fareed J, Walenga JM, Hopensteadt D, Markwardt F. In vitro studies in thrombin generation in citrated, r-hirudinized and heparinized whole blood. Semin Thromb Res 64:589, 1991.
Gallitz S, Muntean W. Thrombin-hirudin complex formation, thrombin-antithrombin III complex formation, and thrombin generation after intrinsic activation of plasma. Thromb Haemost 72:387, 1994.
Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 19:1065, 1992.
Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, Broccolino M, Mannuci PM, Rosenberg RD. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 25:203, 1995.
Ewald GA, Eisenberg PR. Plasmin-mediated activation of the contact system in response to pharmacologic thrombolysis. Circulation 91:28, 1995.
Scharfstein JS, Abendschein DR, Eisenberg PR, George D, Cannon CP, Becker RC, Sobel BE, Cupples LA, Braunwald E, Loscalzo J, for the TIMI-5 Investigators. Fibrino(geno)lytic and procoagulant markers during thrombolytic therapy with rt-PA and adjunctive antithrombotic therapy predict clinical outcomes. Am J Cardiol 78:503, 1996.
Nossel HL, Yudelman RE, Canfield VP, Butler VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 54:43, 1974.
Blomback B, Hessel B, Hogg D, Therkidsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature 275:501, 1978.
Blomback B, Vestermark A. Isolation of fibrinopeptides by chromatography. Arkiv Kemi 12:173, 1958.
Bilizekian SB, Nossel HL, Butler VP, Canfield R. Radioimmunoassay of human fibrinopeptide B and kinetics of fibrinopeptide cleavage by different enzymes. J Clin Invest 6:438, 1975.
Laudano AP, Doolittle RF. Influence of calcium ion on the binding of fibrin amino terminal peptides to fibrinogen. Science 212:457, 1981.
Hermans J, McDonagh J. Fibrin: Structure and interactions. Semin Thromb Hemost 8:11, 1982.
Shainoff J, Page T. Significance of cryoprofibrin in fibrinogen-fibrin conversion. J Exp Med 116:687, 1962.
Yudelman IM, Nossel HL, Kaplan KL, Hirsh J. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood 51:1189, 1978.
Blomback B, Blomback M, Edman P, Hessel B. Human fibrinopeptides: Isolation, characterization and structure. Biochim Biophys Acta 115:371, 1966.
Koehn JA, Canfield RE. Purification of human fibrinopeptides by high performance liquid chromatography. Anal Biochem 116:349, 1981.
Seydewitz HH, Witt I. Increased phosphorylation of human fibrinopeptide A under acute phase conditions. Thromb Res 40:29, 1985.
Alkjaersig N, Fletcher AP. Catabolism and excretion of fibrinopeptide A. Blood 60:148, 1982.
Leeksma OC, Meijer-Huizinga F, Stoepman-van Dalen EA, van Aken WG, van Mourik JA. Fibrinopeptide A in urine from patients with venous thromboembolism, disseminated intravascular coagulation and rheumatoid arthritis — evidence for dephosphorylation and carboxyterminal degradation of the peptide by the kidney. Thromb Haemost 54:792, 1985.
Wilensky RL, Zeller JA, Wish M, Tulchinsky M. Urinary fibrinopeptide A levels in ischemic heart disease. J Am Coll Cardiol 14:597, 1989.
Nossel H, Younger L, Wilner G, Procupez T, Canfield R, Butler VPJ. Radioimmunoassay of human fibrinopeptide A. Proc Natl Acad Sci USA 68:2350, 1971.
Wilner GD, Nossel HL, Canfield RE, Butler VPJ. Immunochemical studies of human fibrinopeptide A using synthetic peptide homologues. Biochemistry 15:1209, 1976.
Soulier J. A new adsorption agent for coagulation factors. J Clin Pathol 12:303, 1959.
Soulier JP, Prou-Wartelle O. Action de divers “adsorbants” sur les facteurs de coagulation. Nouv Rev Ft Hematol 15:195, 1975.
Cronlund M, Hardin J, Burton J, Lee L. Haber E, Bloch K. Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosis. J Clin Invest 58:142, 1976.
Kockum C. Radioimmunoassay of fibrinopeptide A: clinical applications. Thromb Haemost 8:225, 1976.
Gerrits W, Flier O, Meer JVD. Fibrinopeptide A immunoreactivity in human plasma. Thromb Res 5:197, 1974.
Budzynski A, Marder V. Determination of human fibrinopeptide A by radioimmunoassay in purified systems and in the blood. Thromb Diath Haemorrh 34:709, 1975.
Nossel HL, Butler VP, Wilner GD, Canfield RE, Harfenist EJ. Specificity of antisera to human fibrinopeptide A used in clinical fibrinopeptide A assays. Thromb Haemost 35:101, 1976.
Kudryk B, Robinson D, Netre C, Hessel B, Blomback M, Blomback B. Measurement in human blood of fibrinogen/fibrin fragments containing the Bβ15–42 sequence. Thromb Res 25:277, 1982.
Nossel ML, Butler VP, Canfield AG, Yudelman I, Kalliope-Spanondis MT, Soland T. Potential use of fibrinopeptide A measurement in the diagnosis and management of thrombosis. Thromb Diathes Haemorrh 33:426, 1975.
Eisenberg PR. Novel antithrombotic strategies for the treatment of coronary artery thrombosis: A critical appraisal. J Thromb Thrombolysis 1:237, 1995.
Hotchkiss KA, Chesterman CN, Hogg PJ. Inhibition of heparin activity in plasma by soluble fibrin: Evidence for ternary thrombin-fibrin-heparin complex formation. Blood 84:498, 1994.
Eckhardt J, LaGama KS, Nossel HL. Measurement of des arginine fibrinopeptide B (des-arg-FPB) in plasma by radioimmunoassay. Thromb Haemost 42:97, 1979.
De Boer AC, Turpie AGG, Butt RW, Duke RJ, Bloch RF, Genton E. Plasma betathromboglobulin and serum fragment E in acute partial stroke. Br J Haematol 50:327, 1982.
Lane DA, Wolff S, Ireland H, Gawel M, Foadi M. Activation of coagulation and fibrinolytic systems following stroke. Br J Haemarol 53:655, 1983.
Hofmann V, Straub PW. A radioimmunoassay technique for the rapid measurement of human fibrin-opeptide A. Thromb Res 11:171, 1977.
Peuscher FW, van Aken WG, Flier OTN, Stoepman-van Dalen EA, Cremer-Goote TM, van Mourik JA. Effect of anticoagulant treatment measured by fibrin-opeptide A (fpA) in patients with venous throm-boembolism. Thromb Res 18:33, 1980.
Rickles FR, Edwards RL, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A and tumor growth. Cancer 51:301, 1983.
Ireland H, Lane DA, Wolff S, Foadi M. In vivo platelet release in myeloproliferative disorders. Thromb Haemost 48:41, 1982.
Douglas JT, Lowe GDO, Forbes CD, Prentice CRM. Plasma fibrinopeptide A and β-thromboglobulin in patients with chest pain. Thromb Haemost 50:541, 1983.
Eisenberg PR, Sherman LA, Dickens J, Perez J, Jaffe AS. Detection of mural thrombus by assay of fibrinopeptide A (FPA) in plasma. Circulation 72:249, 1985.
Meade TW, Howarth DJ, Stirling Y, Welch TP, Crompron MR. Fibrinopeptide A and sudden coronary death. Lancet 2:607, 1984.
Nichols AB, Owen J, Kaplan KL, Sciacca AR, Cannon PJ, Nossel HL. Fibrinopeptide A, platelet factor 4, and betathromboglobulin levels in coronary heart disease. Blood 60:650, 1982.
Wilner GD, Chatpar P, Amanda T, Horowitz J. Effects of extravascular clotting on fibrinopeptide A levels in blood. J Lab Clin Med 91:205. 1978.
Serneri GGN, Gensini GF, Carnovali M, Prisco D, Rogasi PG, Casolo GC, Fazi A, Abbate R. Association between time of increased fibrinopeptide A levels in plasma and episodes of spontaneous angina: A controlled prospective study. Am Heart J 113:672, 1987.
Ardissino D, Gamba MG, Merlini PA, Rolla A, Barberis P, Demicheli G, Testa S, Bruno N, Specchia G. Fibrinopeptide A excretion in urine: A marker of the cumulative thrombin activity in stable versus unstable angina patients. Am J Cardiol 68:58B, 1991.
Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: A marker of acute coronary thrombosis. Circulation 71:912, 1985.
Eisenberg PR, Kenzora JL, Sobel BE, Ludbrook PA, Jaffe AS. Relation between ST segment shifts during ischemia and thrombin activity in patients with unstable angina. J Am Coll Cardiol 18:898, 1991.
Wilensky RL, Bourdillon PDV, Vix VA, Zeller JA. Intracoronary artery thrombus formation in unstable angina: A clinical, biochemical, and angiographic correlation. J Am Coll Cardiol 21:692, 1993.
van Hultsteijn H, Kolff J, Briet E, van der Laarse A, Bertina R. Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction. Am Heart J 107:39, 1984.
Mombelli G, Im Hof V, Haeberli A, Straub PW. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. Circulation 69:684, 1984.
Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ. Shelton ME, Winters KJ. Association of heparinresistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 94:2064, 1996.
Gallino A, Haeberli A, Hess T, Mombelli G, Straub PW. Fibrin formation and platelet aggregation in patients with acute myocardial infarction: Effects of intravenous and subcutaneous low-dose heparin. Am Heart J 112:285, 1986.
Eisenberg PR, Sherman LA, Rich M, Schwartz D, Schectman K, Geltman EM, Sobel BE, Jaffe AS. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 7:1255, 1986.
Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 72:616, 1988.
Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A: Evidence for continued thrombosis despite intensive fibrinolysis. J Am Coll Cardiol 10:527, 1987.
Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol 24:1445, 1994.
Rapold HJ, Kuemmerli H, Weiss M, Baur H, Haeberli A. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 79:980, 1989.
Rapold HJ. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet 1:481, 1990.
Reganon E, Vila V, Aznar J, Lacueva V, Martinez V, Ruano M. Studies on the functionality of newly synthesized fibrinogen after treatment of acute myocardial infarction with streptokinase, increase in the rate of fibrinopeptide release. Thromb Haemost 70:978, 1993.
Weitz JI, Cruickshank MK, Thong B, Leslie B, Levine MN, Ginsberg J, Eckhardt T. Human tissuetype plasminogen activator releases fibrinopeptides A and B from fibrinogen. J Clin Invest 82:1700, 1988.
Carlson TH, Simon TL, Atencio AC. In vivo behavior of human radioiodinated antithrombin III: Distribution among three physiologic pools. Blood 66:13, 1985.
Teitel JM, Rosenberg RD. Protection of factor Xa from neutralization by heparin-antithrombin complex. J Clin Invest 71:1383, 1983.
Gulba DC, Bartheis M, Westhoff-Bleck M, Jost S, Wolff R, Daniel WG, Hecker H, Lichtlen PR. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. Circulation 83:937, 1991.
Blanke H, Praetorius G, Leschke M, Seitz R, Egbring R, Strauer BE. Die bedeutung des thrombin-antithrombin HI-komplexes in der diagnostik der lungenembolie und der tiefen venenthrombose-vergleich mit fibrinopeptide A, plattchenfaktor 4 und β-thrombulin. Klin Wochenschr 65:757, 1987.
Seitz R, Blanke H, Pratorius G, Strauer BE, Egbring R. Increased thrombin activity during thrombolysis. Thromb Haemost 59:541, 1988.
Lau HK, Rosenberg RD. The isolation and characterization of a specific antibody directed against the thrombin-antithrombin complex. J Biol Chem 255:5885, 1980.
Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 59:101, 1988.
Bounameaux H, Schneider PA, Reber G, Moerloose PD, Krahenbuhl B. Measurement of plasma D-dimer for diagnosis of deep venous thrombosis. Am J Clin Pathol 91:82, 1989.
Demers C, Ginsberg JS, Johnston M, Brill-Edwards P, Panju A. D-dimer and thrombin-antithrombin III complexes in patients with clinically suspected pulmonary embolism. Thromb Haemost 67:408, 1992.
Giansante C, Fiotti N, Cattin L, Col PGD, Calabrese S. Fibrinogen, D-dimer and thrombin-antithrombin complexes in a random population sample: Relationships with other cardiovascular risk factors. Thromb Haemost 71:581, 1994.
Lassila R, Peltonen S, Lepantolo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral arteriosclerosis is associated with fibrinogen and degradation products of cross-linked fibrin. Arterioscler Thromb 13:1738, 1993.
Garcia-Avello A, Garcia-Frade LJ, Gandarias C, Ocana J, Cancelas JA, Lasso M. High F1.2 fragment of prothrombin. Thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA. Thromb Res 73:109, 1994.
Eritsland J, Selfjeflot I, Arnesen H, Smith P, Westvik AB. Effects of long-term treatment with warfarin on fibrinogen, FPA, TAT, and D-dimer in patients with coronary artery disease. Thromb Res 66:55, 1992.
Wilf J, Minton AP. Soluble fibrin-fibrinogen complexes as intermediates in fibrin gel formation. Biochemistry 25:3124, 1986.
Mehs DA, Siebenlist KR, Bergstrom G, Mosesson MW. Sequences of release of fibrinopeptide A from fibrinogen molecules by thrombin or Atraxin. J Lab Clin Med 125:384, 1995.
Smith GF. The mechanisms of fibrin-polymer formation in solution. Biochem J 185:1, 1980.
Alkjaersig N, Fletcher AP. Formation of soluble fibrin oligomers in purified systems and in plasma. Biochem J 213:75, 1983.
Dietler G, Kanzig W, Haeberli A, Straub PW. Experimental tests of a geometrical abstraction of fibrin polymerization. Biopolymers 25:905, 1986.
Hunziker EB, Srraub PW, Haeberli A. A new concept of fibrin formation based upon linear growth of interlacing and branching polymers and molecular alignment into interlocked single-stranded segments. J Biol Chem 265:7455, 1990.
Janmey PA, Erdile L, Bale MD, Ferry JD. Kinetics of fibrin oligomer formation observed by electron microscopy. Biochemistry 22:4336, 1983.
Fletcher AP, Alkjaersig NK, Ghani FM, Tulevski V, Owens O. Blood coagulation system pathophysiology in acute myocardial infarction: The influence of anticoagulant treatment on laboratory findings. J Lab Clin Med 93:1054, 1979.
Kruskal JB, Commeford PJ, Franks JJ, Kirsch RE. Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 317:1361, 1987.
Magari Y, Mizunga S, Ito M, Shibaca T, Ito H. Molecular marker for detecting hypercoagulable state. Jpn J Clin Pathol 42:22, 1994.
Lane DA. Fibrinogen derivatives in plasma. Br J Haematol 47:329, 1981.
Eisenberg PR, Jaffe AS, Stump DC, Collen D, Bovill EG. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis. Circulation 82:1159, 1990.
Shainoff R, Urbanie DA, DiBello PM, Valenzuela V. GPR-phoresis, a novel approach to determining fibrin monomer and other macromolecular derivatives of fibrinogen and fibrin in blood. Blood Coagul Fibrinolysis 4:87, 1993.
Nieuwenhuizen W, Nobel EH, Laterveer R. A rapid immunoassay (EIA) for rhe quantitative determination of soluble fibrin in plasma. Thromb Haemost 68:273, 1992.
Rylatt DB, Blake AS, Cottis DA, Massingham DA, Fletcher WA, Masci PP, Whitaker AN, Elms M, Bunce I, Webber AJ, Wyatt D, Bundesen PG. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res 31:767, 1983.
Dinh D, Bolitho J, Bundensen P, Hillyard C, Marsh N, Moore B, Bottenus R, Rylatt D. Detection of soluble fibrin by enzyme immunoassay. Fibrinolysis 8(Suppl. 1):125, 1994.
Lee LV, Ewald G, McKenzie C, Eisenberg PR. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction. Arterioscler Thromb Vasc Biol 17:628, 1996.
Kisiel W. Human protein C: Isolation, characterisation, and mechanism of activation by alphathrombin. J Clin Invest 64:761, 1979.
Kisiel W, Canfield WM, Ericsson LH, Davie EW. Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry 16:5824, 1977.
Vehar GA, Davie EW. Preparation and properties of bovine factor VIII (antihemophilic factor). Biochemistry 19:401, 1980.
Comp PC, Esmon CT. Activated protein C inhibits platelet prothrombin-converting activity. Blood 54:1272, 1979.
Bauer KA, Kass BL, Beeler DL, Rosenberg RD. Detection of protein C activation in humans. J Clin Invest 74:2033, 1984.
Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans: Normative aging study. J Clin Invest 80:1527, 1987.
Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 43:77, 1980.
Kruithof EKO, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 64:907, 1984.
Thorsen S, Philips M, Selmer J, Lecander I, Astedt B. Kinetics of inhibition of tissue-type and urokinasetype plasminogen activator by plasmingogen-activator inhibitor type 1 and type 2. Eur J Biochem 175:33, 1988.
Lindahl TL, Ohlsson PI, Wiman B. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator. Biochem J 265:109, 1990.
Chmielewska J, Ranby M, Wiman B. Kinetics of the inhibition of plasminogen activator by the plasminogen-activator inhibitor. Evidence for “second-site” interactions. Biochem J 251:327, 1988.
Moroi M, Aoki N. Isolation and characterization of β2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem 251:5956, 1976.
Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 69:209, 1976.
Mullertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 159:545, 1976.
Suenson E, Thorsen S. The course and prerequisites of Lys-plasminogen formation during fibrinolysis. Biochemistry 27:2435, 1988.
Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301:214, 1983.
Ranby M, Bergsdorf N, Nilsson T. Enzymatic properties of the one-and two-chain form of tissue plasminogen activator. Thromb Res 27:175, 1982.
Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 257:2920, 1982.
Tate KM, Higgens DL, Holmes WE, Winkler ME, Heyneker HL, Vehar GA. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 26:338, 1987.
Higgins DL, Vehar GA. Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin. Biochemistry 26:7786, 1987.
Higgins DL, Lamb MC. Incorporation of a fluorescent probe into the active sites of one-and two-chain tissue-type plasminogen activator. Arch Biochem Biophys 249:418, 1986.
Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature 272:549, 1978.
Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 31:427, 1983.
Bu G, Williams S, Strickland DK, Schwartz AL. Low density lipoprotein receptor-related protein/α2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci USA 89:7427, 1992.
Nilsson T, Wallen P, Mellbring G. In vivo metabolism of human tissue-type plasminogen activator. Stand J Haematol 33:49, 1984.
Nilsson S, Einarsson M, Ekvarn S, Haggroth L, Mattsson C. Turnover of tissue plasminogen activator in normal and hepatectomized rabbits. Thromb Res 39:511, 1985.
Fuchs HE, Berger H, Pizzo SV. Catabolism of human tissue plasminogen activator in mice. Blood 65:539, 1985.
Morton PA, Owensby DA, Underhill DM, Schwartz AL. Cellular itinerary of t-PA in human hepatocytes (abstr). Thromb Haemost 65:614, 1991.
Labarrere CA, Pitts D, Halbrook H, Faulk WP. Tissue plasminogen activator in cardiac allografts. Transplantation 55:1056, 1993.
Labarrere CA, Pitts D, Halbrook H, Faulk WP. Tissue plasminogen activator, plasminogen activator inhibitor-1, and fibrin as indexes of clinical course in cardiac allograft recipients: An immunocytochemical study. Circulation 89:1599, 1994.
Faulk WP, Labarrere CA, Pitts D, Halbrook H. Vascular lesions in biopsy specimens devoid of cellular infiltrates: Qualitative and quantitative immunocytochemical studies of human cardiac allografts. J Heart Lung Transplant 12:219, 1993.
Cash JD, Woodneld DG, Allan AGE. Adrenergic mechanisms in the systemic plasminogen activator response to adrenaline in man. Br J Haematol 18:487, 1970.
Ranby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 32:2160, 1986.
De Boer A, Kluft C, Kroon JM, Kasper FJ, Schoemaker HC, Pruis J, Breimer DD, Soons PA, Emeis JJ, Cohen AF. Liver blood How as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. Thromb Haemost 67:83, 1992.
Andreotti F, Davies GJ, Hackett DR, Khan MI, De Bart ACW, Aber VR, Maseri A, Kluft C. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 62:635, 1988.
Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 69:381, 1987.
Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis 5:197, 1991.
Emeis JJ, van Hinsbergh VWM, Verheijen JH, Wijngaards G. Inhibition of tissue-type plasminogen activator by conditioned medium from cultures of human and porcine vascular endothelial cells. Biochem Biophys Res Commun 110:392, 1983.
Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture: Evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA 80:6804, 1983.
Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fuji S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenic link between obesity and cardiovascular disease. Circulation 93:106, 1996.
Laug WE. Vascular smooth muscle cells inhibit the plasminogen activators secreted by endothelial cells. Thromb Haemost 20:165, 1985.
Sprengers ED, Verheijen JH, Van Hinsbergh VWM, Emeis JJ. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochim Biophys Acta 801:163, 1984.
Erickson LA, Hekman CM, Loskutoff DJ. The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci USA 82:8710, 1985.
Hekman CM. Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 260:11581, 1985.
Sprengers ED, Akkerman JWN, Sansen BG. Blood platelet plasminogen activator inhibitor: Two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost 55:325, 1986.
Lindahl TL, Sigurdardottir O, Wiman B. Stability ot plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 62:748, 1989.
Sprengers ED, Van Hinsbergh VWM, Jansen BG. The active and the inactive plasminogen activator inhibitor from human endothelial cell conditioned medium are immunologically and functionally related to each other. Biochim Biophys Acta 883:233, 1986.
Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and-independent mechanisms. Blood 83:351, 1994.
Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor ot plasminogen activator in human platelets. J Clin Invest 74:1465, 1981
Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 70:721, 1987.
Salonen EM, Vaheri A, Pollanen J, Scephens R, Andreasen P, Mayer M, Dano K, Gailit J, Rouslahti E. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 264:6339, 1989.
Sigurdardottir O, Wiman B. Complex formation between plasminogen activator inhibitor I and vitronectin in purified systems and in plasma. Biochim Biophys Acta 1035:56, 1990.
Preissner KT. Structure and biological role of vicronectin. Annu Rev Cell Biol 7:275, 1991.
Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner TK, Pannekoek H. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 265:13029, 1990.
Naski MC, Lawrence DA, Mosher DF, Podor T, Ginsburg D. Kinetics of inactivation of α-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem 268:12367, 1993.
Edelberg JM, Reilly CF, Pizzo SV. The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein (a). J Biol Chem 266:7488, 1991.
Rosenberg RD. The heparin-antithrombin system: A natural anticoagulation mechanism. In Coleman RW, Hirsh J, Marder VJ, Salzman EW (eds). Haemostasis and Thrombosis. Philadelphia: JB Lippincott, 1987:1372.
Edelberg JM, Sane DC, Pizzo SV. Vascular regulation of plasminogen activator inhibitor-1 activity. Semin Thromb Hemost 20:319, 1994.
Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 75:818, 1985.
Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Prog Cardiovasc Dis 34:179, 1991.
Kruithof EKO, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost 59:7, 1988.
Takada Y, Takada A. Measurements of the concentration of free plasminogen activator inhibitor (PAI-1) and its complex with tissue plasminogen activator in human plasma. Thromb Res-Suppl 8:15, 1988.
Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: Low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 290:1453, 1985.
Eriksson E, Ranby M, Gyzander E, Risberg B. Determination of plasminogen activator inhibitor in plasma using t-PA and chromogenic single-point poly-D-lysine stimulated assay. Thromb Res 50:91, 1988.
Jansson JH, Boman K, Nilsson TK. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 44:485, 1993.
Rijken DC, Juhan-Vague I, Collen D. Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay. J Lab Clin Med 101:285, 1983.
Bergsdorf N, Nilsson T, Wallen P. An enzyme linked immunoabsorbenc assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemost 50:740, 1983.
Urden G, Blomback M. Determination of tissue plasminogen activator in plasma samples by means of a radioimmunoassay. Scan J Clin Lab Invest 44:495. 1984.
Takada A, Shizume K, Ozawa T, Takahashi S, Takada Y. Characterization of various antibodies against tissue plasminogen activator using highly sensitive enzyme immunoassay. Thromb Res 42:63, 1986.
Ranby M, Nguyen G, Scarabin PY, Samama M. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes: Biochemical and multicenter validation of a two site immunosorbent assay. Thromb Haemost 61:409, 1989.
Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: Its role in thrombotic disease. Thromb Haemost 74:71, 1995.
Kluft C, Verheijen JH. Leiden Fibrinolysis Working Party: Blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis 4:155, 1990.
Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 79:101, 1989.
Grimaudo V, Hauert J, Bachemann F, Kruithof EKO. Diurnal variation of the fibrinolytic system. Thromb Haemost 59:495, 1988.
Huber K, Rose D, Resch I, Schuster F., Glogar DH, Kaindl F, Binder BR. Circadian fluctuation of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost 60:372, 1988.
Emeis JJ, Kooistra T. Interleukin-I and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 163:1260, 1986.
Alessi M, Juhan-Vague I, Kooistra T, Declerck P, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepato-cellular cell line Hep G2. Thromb Haemost 60:491. 1988.
Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type-1: Implications for vascular disease by hyperinsulinemic states. Proc Natl Acad Sci USA 88:9959, 1991.
Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 10:1067, 1990.
Larron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 11:1821, 1991.
Tremoli F., Camera M, Maderna P, Sironi L, Prati L, Colli S, Piovella F, Bernini F, Corsini A, Mussoni L. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. Arterioscler Thromb 13:338, 1993.
Juhan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 33:523, 1984.
Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 57:67, 1987.
Mellbring G, Dahlgren D, Wiman B, Sunnegardh O. Relationship between preoperative status of the fibrinolytic system and occurrence of deep vein thrombosis after major abdominal surgery. Thromb Res 39:157, 1985.
Wiman B, Chmielewska J. A novel fast inhibitor to tissue plasminogen activator in plasma, which may be of great pathophysiological significance. Scand J Clin Lab Invest 45:43, 1985.
Juhan-Vague 1, Aillard MF, DeCock F. The rapid inhibitor of tissue-type plasminogen activator is an acute phase reactant protein. In Darden JF, Donati MB, Coccheri S (eds). Progress in Fibrinolysis, Vol. VII. Edinburgh: Churchill Livingstone, 146, 1985.
Kluft C, Verheijen JH, Jie AFH, Rijken DC, Preston FE, Sue-Ling HM, Jespersen J, Aasen AO. The postoperative fibrinolytic shutdown: A rapidly-reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scan J Clin Lab Invest 45:605, 1985.
Kruithof EKO, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitors. Blood 69:460, 1987.
Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome: A study of 1500 patients with angina pectoris. Arterioscler Thromb 13:1865, 1993.
Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL, triglyceride concentration, insulin levels and insulin sensitivity: Studies in randomly selected normo-and hypertriglyceridemic men. Diabetologia 36:817, 1993.
Mansfield MW, Stockland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promotes polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 74:1032, 1995.
Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor-I levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34:457, 1991.
Folsom AR, Qamheih HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 13:162, 1993.
Sundell IB, Dahlgren S, Ranby M, Lundin E, Stenling R, Nilsson TK. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis 3:51, 1989.
Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost 63:174, 1990.
Mehrabian M, Peter JB, Barnard RJ, Lusis AJ. Dietary regulation of fibrinolytic factors. Atherosclerosis 84:25, 1990.
Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasmin insulin level, and relative body weight in normal and obsese subjects. Metabolism 35:250, 1986.
Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39:1044, 1990.
Wall U, Jern C, Bergbrant A, Jem S. Enhanced levels of tissue-type plasminogen activator in borderline hypertension. Hypertension 26:796, 1995.
Licata G, Scaglione R, Avellone G, Ganguzza A, Corrao S, Arnone S, Chiara TD. Hemostatic function in young subjects with central obesity: Relationship with left ventricular function. Metabolism 44:1417, 1995.
Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Weltry FK, Wilson PWF, Levy D, Muller JE, Tofler GH. Association between increased estrogen status and increased fibrinolytic potential in the Framingham offspring study. Circulation 91:1952, 1995.
Smokovitis A, Kokolis N, Taitzoglou I. Sex-related differences in plasminogen activator activity and plasminogen activator inhibition of human and animal kidneys: Effect of orchiectomy or ovariectomy. Haemostasis 21:305, 1991.
Meilahn E, Cauley JA, Tracy RP, Macy EO, Gutai JH, Kuller LH. Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Am J Epidemiol 143:159, 1996.
Jansson JH, Johansson B, Boman K, Nilsson TK. Hypofibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med 229:309, 1991.
Gleerup G, Winther K. Decreased fibrinolytic activity and increased platelet function in hypertension: Possible influence of calcium antagonism. Am J Hypertens 4:168S, 1991.
van Wersch JWJ, Rompleberg-Lahaye J, Lustermans FAT. Plasma concentration of coagulation and fibrinolysis facrors and platelet function in hypertension. Eur J Clin Chem Clin Biochem 29:375, 1991.
Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 87:1969, 1993.
Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the reninsodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324:1098, 1991.
Rouleau JL, de Champlain J, Klein M, Bichet D, Moye L, Packer M, Dagenais G, Sussex B, Arnold JM, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy E, Lamas G, Gottlieb S, McCans J, Nadeau C, Delage F, Hamm P. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 22:390, 1993.
Wright RA, Flapan AD, Albert KGMM, Ludlam CA, Fox KAA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 24:67, 1994.
Vaughn DE, Rouleau JL, Pfeffer MA. Role of the fibrinolytic system in preventing myocardial infarction. Eur Heart J 16:31, 1995.
Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Nat Acad Sci USA 89:6998, 1992.
Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscl Thromb 13:1090, 1993.
Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemosr 72:44, 1994.
Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: Correlation with age and serum triglyceride concentration. J Am Coll Cardiol 9:263, 1987.
Cortellaro M, Confrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: A case-control study. Arterioscler Thromb 13:1412, 1993.
Oseroff A, Krishnamurti C, Hassett A, Tang D, Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 113:88, 1989.
Vandekerckhove Y, Baele G, de Puydt H, Weyne A, Clement D. Plasma tissue plasminogen activator levels in patients with coronary heart disease. Thromb Res 50:449, 1988.
Paramo JA, Colucci M, Collen D, van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 291:573, 1985.
Sakata K, Kurata C, Taguchi T, Suzuki S, Kobayashi A, Yamazaki N, Rydzewski A, Takada Y, Takada A. Clinical significance of plasminogen activator inhibitor activity in patients with exercise-induced ischemia. Am Heart J 120:381, 1990.
Aimer LO, Ohlin H.Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction. Thromb Res 47:335, 1987.
Aznar J, Estelles A, Tormo G, Sapena P, Tormo V, Blanch S, Espana F. Plasminogen acrivator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 59:535, 1988.
ECAT, Angina Pectoris Study Group. ECAT angina pectoris study: Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 14:8, 1993.
Huber K, Resch I, Stefenelli T, Lang I, Probst P, Kaindl F, Binder BR. Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis. Thromb Haemost 63:336, 1990.
Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 10:77, 1989.
Zalewski A, Shi Y, Nardone D, Bravette B, Weinsrock P, Fischman D, Wilson P, Goldberg S, Levin DC, Bjornsson TD. Evidence for reduced fibrinolytic activity in unstable angina at rest: Clinical, biochemical and angiographic correlates. Circulation 83:1685, 1991.
Verheugt FW, ten Cate JW, Sturk A, Imandt L, Verhorst PM, van Eenige MJ, Verwey W, Roos JP. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol 59:1075, 1987.
Johnson O, Mellbring G, Nilsson T. Defective fibrinolysis in survivors of myocardial infarction. Int J Cardiol 6:380, 1984.
Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313:1557, 1985.
Hamsten A, Walldius G, Szamosi A, Blomback M, de Faire U, Dahlen G, Landou C, Wiman B. Plasminogen activator inhibiror in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3, 1987.
Nilsson TK, Johnson O. The extrinsic fibrinolytic system in survivors of myocardial infarction. Thromb Res 48:621, 1987.
Meade TW, Ruddock V, Stirling Y, Charkrabarti R, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342:1076, 1993.
Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341:1165, 1993.
Gram J, Jespersen J, Kluft C, Rijken DC. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction. Acta Med Scand 221:149, 1987.
Munkvad S, Gram J, Jespersen J. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 11:525, 1990.
Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 12:157, 1991.
Jansson JH, Olofsson NO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 88:2030, 1993.
Sakata K, Miura F, Sugino H, Shinobe M, Shirotani M, Yoshida H, Mori N, Hoshino T, Takada A. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 131:1, 1996.
Kirschstein W, Simianer S, Dempfle CE, Keller H, Stegaru B, Rentrop P, Heene DL. Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty. Thromb Flaemost 62:772, 1989.
Saito M, Nakabayashi T, Iuchi K, Ishikawa T, Kaseno K, Yoshida T, Asakura H, Matsuda T. Effects of direcr percutaneous transluminal coronary angioplasty treatment of acute myocardial infarction on plasma levels of haemostatic and fibrinolytic factors. Blood Coagul Fibrinolysis 4:801, 1993.
Hara M, Ito K, Nawata T, Tsunematsu Y, Shimoyama N, Maeda T, Sato Y, Saikawa T, Sakata T. Plasminogen activator inhibiror-1, tissue plasminogen activator and serum lipoprotein (a) after reperfusion therapy in acure myocardial infarction: Comparison between sequential and direct percutaneous transluminal coronary angioplasty. Cardiology 86:407, 1995.
Sakamoto T, Yasue H, Ogawa H, Misumi I, Masuda T. Association of patency of the infaret-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction. Am J Cardiol 70:271, 1992.
Hirashima O, Ogawa H, Oshima S, Sakamoto T, Honda Y, Sakata S, Masuda T, Miyao Y, Yasue H. Serial changes of plasma plasminogen activator inhibitor activity in acute myocardial infarction: Difference between thrombolytic therapy and direct coronary angioplasty. Am Heart J 130:933, 1995.
Haider AW, Andreotti F, Hackett DR, Tousoulis D, Kluft C, Maseri A, Davies GJ. Early spontaneous intermittent myocardial reperfusion during acute myocardial infarction is associated with augmented thrombogenic activity and less myocardial damage. J Am Coll Cardiol 26:662, 1995.
van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: An update. Fibrinolysis 9:263, 1995.
Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 427:1729, 1992.
Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by plasminogen activator inhibitor type-1 from platelets. Thromb Res 72:413, 1993.
Robbie LA, Both NA, Croll AM, Bennett B. The roles of α2-anciplasmin and plasminogen activator inhibitor 1 (PAI-1) in rhe inhibition of clot lysis. Thromb Haemost 70:301, 1993.
Reed GL, Matsueda GR, Haber E. Platelet factor XIII increases the fibrinolytic resistance of plateletrich clots by accelerating the crosslinking of α2-antiplasmin to fibrin. Thromb Haemost 68:315, 1992.
Sabovic M, Lijnen H, Keber D, Collen D. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost 62:1083, 1989.
Wiman B, Haegerstrand-Bjorkman M. Plasmin/ α2-antiplasmin complex in plasma — a global fibrinolytic assay (abstr). Thromb Haemost 69:1091, 1993.
Collen D, de Cock F, Cambiaso CL, Masson P. A latex agglutination test for rapid quantitative estimation of the plasmin-antiplasmin complex in human plasma. Eur J Clin Invest 7:21, 1977.
Plow EF, de Cock F, Collen D. Immunochemical characterization of the plasmin-antiplasmin system. Basis for the specific detection of the plasmin-antiplasmin complex by latex agglutination assays. J Lab Clin Med 93:199, 1979.
Collen D, Wiman B. Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. Blood 53:313, 1979.
Holvoet P, Lijnen H, Collen D. Monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: Useful to monitor fibrinogen breakdown during t-PA infusion. Blood 67:1482, 1986.
Mimuro J, Koike Y, Sumi Y, Aoki N. Monoclonal antibodies to discrete regions in α2-plasmin inhibitor. Blood 69:446, 1987.
Montes R, Paramo JA, Angles-Cano E, Rocha E. Development and clinical application of a new ELISA assay to determine plasmin-alpha 2-antiplasmin complexes in plasma. Br J Haematol 92:979, 1996.
Nossel HL, Wasser J, Kaplan KL, LaGamma KS, Yudelman I, Canfield RE. Sequence of fibrinogen proteolysis and platelet release after intra-uterine infusion of hypertonic saline. J Clin Invest 64:1371, 1979.
Marder VJ, Francis CW, Doolittle RF. Fibrinogen Structure and Physiology. In Haemostasis and Thrombosis. Philadelphia: JB Lippincott, 1982.
Jaffe AS, Eisenberg PR, Wilner GD. In vivo assessment of thrombosis and fibrinolysis during acute myocardial infarction. Prog Hematol 15:71, 1987.
McDonagh RP, McDonagh J, Ducken F. The influence of fibrin crosslinking on the kinetics of urokinase-induced clot lysis. Br J Haematol 21:323, 1971.
Gaffney PJ, Creighton LJ, Callus M, Thorpe R. Monoclonal antibodies to crosslinked fibrin degradation products (XL-FDP). II. Evaluation in a variety of clinical conditions. Br J Haematol 68:91, 1988.
Kroneman H, Nieuwenhuizen W, Knute A. Monoclonal amibody-based plasma assays for fibrin(ogen) and derivatives and their clinical relevance. Blood Coagul Fibrinolysis 1:91, 1990.
Gaffney PJ, Perry MJ. Unreliability of current serum fibrin degradation product assays. Thromb Haemost 53:301, 1985.
Merskey C, Kleiner GJ, Johnson AJ. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood 28:1, 1966.
Budzynski AZ, Marder VJ, Parker ME, Shames P, Brizuela BS, Olexa SA. Antigenic markers on fragment DD, a unique plasmic derivative of human crosslinked fibrin. Blood 54:794, 1979.
Lee-Owen V, Gordon YB, Chard T. The detection of neoantigenic sites on the D-dimer peptide isolated from plasmin digested cross linked fibrin. Thromb Res 14:77, 1979.
Siefried E, Tanswel P, Rijken DC, Kluft C, Hoegee E, Nieuwenhuizen W. Fibrin degradation products are not specific markers for thrombolysis in myocardial infarction. Lancet 2:333, 1987.
Whitaker AN, Elms MJ, Masci PP, Bundesen PG, Rylatt DB, Weber AJ, Bunce IH. Measurement of crosslinked fibrin derivatives in plasma: An immunoassay using monoclonal antibodies. J Clin Pathol 37:882, 1984.
Eisenberg PR, Sherman LA, Perez J, Jaffe AS. Relationship between elevated plasma levels of cross-linked fibrin degradation products (XL-FDP) and the clinical presentation of patients with myocardial infarction. Thromb Res 46:109, 1987.
Koppert PW, Kuipers W, Hoegee-de Nobel B, Brommer EJP, Koopman J, Nieuwenhuizen W. A quantitative enzyme immunoassay for primary fibrinogenolysis products in plasma. Thromb Haemost 57:25, 1987.
Koopman J, Haverkate F, Koppert P, Niewenhuizen W, Brommere JP, van der Werf VGC. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody. J Lab Clin Med 109:75, 1987.
Declerck PJ, Mombaerts P, Holvoet P, de Mol M. Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemost 58:1024, 1987.
Lawler CW, Bovill EG, Stump DC, Collen DJ, Mann KG, Tracy RP. Fibrin fragment D-dimer and fibrinogen Bβ peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. Blood 76:1341, 1990.
Hart R, Bate I, Dinh D, Elms M, Bundesen P, Hillyard C, Rylatt DB. The detection of D-dimer in plasma by enzyme immunoassay: Improved discrimination is obtained with a more specific signal antibody. Blood Coagul Fibrinolysis 5:227, 1994.
Ballegeer V, Mombaerts P, Declerck PJ, Spitz B, Van Asche FA, Collen D. Fibrinolytic response to venous occlusion and fibrin fragment D-dimer levels in normal and complicated pregnancy. Thromb Haemost 58:1030, 1987.
Soria C, Soria J, Mirshashi MC, Mirshashi M, Dunnica S, Bousheix C, Beaufils R, Sluma R, Caen JP. Dynamic coronary fibrinolysis evaluation in patients with myocardial infarction and unstable angina by specific plasma fibrin degradation product determination. Thromb Res 45:383, 1987.
Hunt FA, Rylatt DB, Hart RA, Bundesen PG. Serum crosslinked fibrin (XDP) and fibrinogen/fibrin degradarion products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems. Br J Haematol 60:715, 1985.
Chapman CS, Akhtar N, Campbell S, Miles K, O’Connor J, Mitchell VE. The use of D-dimer assay by enzyme immunoassay and latex agglutination techniques in the diagnosis of deep vein thrombosis. Clin Lab Haemat 12:37, 1990.
Carter CJ, Doyle DL, Dawson N, Fowler S, Devine DV. Investigations into the clinical utility of latex D-dimer in the diagnosis of deep venous thrombosis. Thromb Haemost 69:8, 1993.
Koopman MMW, Brandjes DPM, Beek EJR, Turkstra F, Buller HR. Sensitivity and specificity of a bed-side whole blood latex D-dimer assay (SimpliRED®) in outpatients with deep vein thrombosis. Thromb Haemost 73:1100, 1995.
Elias A, Aillaud MF, Roul C, Monteil O, Villain PH, Serradimigni A, Juhan-Vague I. Assessment of D-dimer measurement by ELISA or latex methods in deep vein thrombosis diagnosed by ultrasonic duplex scanning. Fibrinolysis 4:237, 1990.
Chang-Liem GS, Lustermans FA, van Wersch JWJ. Comparison of the appropriateness of the latex and ELISA plasma D-dimer determination for the diagnosis ot deep venous thrombosis. Haemostasis 21:106, 1991.
John MA, Elms MJ, O’Reilly EJ, Rylatt DB, Bundesen PG, Hillyard CJ. The SimpliRED D-dimer test: A novel assay for the detection of crosslinked fibrin degradation products in whole blood. Thromb Res 58:273, 1990.
Deitcher SR, Eisenberg PR. Elevated concentrations of cross-linked fibrin degradation products in plasma. Chest 103:1107, 1993.
Brenner B, Pery M, Lanir N, Jabareen A, Markel A, Kaftori JK, Gaitini D, Rylatt D. Application of a bedside whole blood D-dimer assay in the diagnosis of deep vein thrombosis. Blood Coagul Fibrinolysis 6:219, 1995.
Wells PS, Brill-Edwards P, Stevens P, Panju A, Patel A, Douketis J, Massicotte P, Hirsh J, Weitz JI, Kearon C, Ginsberg JS. A novel and rapid whole-blood assay for D-dimer in patients with clinically suspected deep vein thrombosis. Circulation 91:2184, 1995.
Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Panju A, Beek EJR, Patel A. Application of a novel and rapid whole blood assay for D-dimer in patients with clinically suspected pulmonary embolism. Thromb Haemost 73:35, 1995.
Bounameaux H, Cirafici P, Moerloose PD, Slosman D, Reber G, Linger PF. Measurement of D-dimer in plasma as a diagnostic aid in suspected pulmonary embolism. Lancet 337:196, 1991.
Goldhaber SZ, Vaughan DE, Tumeh SS, Loscalzo J. Utility of cross-linked fibrin degradation products in the diagnosis of pulmonary embolism. Am Heart J 116:505, 1989.
Rowbotham BJ, Egerton-Vernon J, Whitaker AN, Elms MJ, Bunce IH. Plasma cross linked fibrin degradation products in pulmonary embolism. Thorax 45:684, 1990.
Lichey J, Reschofski I, Dissmann T, Priesnitz M, Hoffmann M, Lode H. Fibrin degradation product D-dimer in the diagnosis of pulmonary embolism. Klin Wochenschr 69:522, 1991.
Rowbotham BJ, Carroll P, Whitaker AN, Bunce IH, Cobcroft RG, Elms MJ, Masci PP, Bundesen PG, Rylatt DB, Webber AJ. Measurement of crosslinked fibrin derivatives — use in the diagnosis of venous thrombosis. Thromb Haemost 57:59, 1987.
Ott P, Astrup L, Hartving JR, Nyeland B, Pedersen B. Assessment of D-dimer in plasma: Diagnostic value in suspected deep venous thrombosis of the leg. Acta Med Scand 224:263, 1988.
Lee AJ, Fowkes FGR, Lowe GDO, Rumley A. Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost 3:828, 1995.
Bredbacka S, Edner G. Soluble fibrin and D-dimer as detectors ot hypercoagulability in patients with isolated brain trauma. J Neurosurg Anesthesiol 6:75, 1994.
Eisenberg PR, Sobel BE, Jaffe AS. Characterization in vivo of the fibrin specificity of activators of the fibrinolytic system. Circulation 78:592, 1988.
Eisenberg PR, Sherman LA, Tiefenbrunn AJ, Ludbrook PA, Sobel BE, Jaffe AS. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation. Thromb Haemost 57:35, 1987.
Vaughan DE, Goldhaber SZ, Kim J, Loscalzo J. Recombinant tissue plasminogen activator in patients with pulmonary embolism: Correlation of fibrinolytic specificity and efficacy. Circulation 75:1200, 1987.
Ridker PM, Hennekens CH, Cerskers A, Stampfer MJ. Plasma concentration of cross-linked fibrin deg-radation products (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 90:2236, 1994.
Abe S, Maruyama I, Arima S, Yamaguchi H, Okino H, Hamasaki S, Yamashita T, Nomoto K, Tahara M, Atsuchi Y, Nakao S, Tanaka H. Increased heparin-releasable platelet factor 4 and D-dimer in patients 1 month after the onset of acute myocardial infarction: Persistent activation of platelets and the coagulation/fibrinolytic system. Int J Cardiol 47:S7, 1994.
Fowkes FGR, Lowe GDO, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Crosslinked fibrin degradation products, progression of peripheral artery disease, and risk ot coronary heart disease. Lancet 342:84, 1993.
Ring ME, Vecchione JJ, Fiore LD, Ruocco NA, Jacobs AK, Deykin D, Ryan TJ, Faxon DP. Detection of intracoronary fibrin degradation aftercoronary balloon angioplasty. Am J Cardiol 67:1330, 1991.
Jorgensen B, Nielsen JD, Norgard J, Helligso P, Baekgaard N, Egeblad M. Cross-linked fibrin degradation products (XL-FDP) as markers of early rethrombosis in percutaneous transluminal angioplasty. Eur J Vasc Surg 7:720, 1993.
Weitz JI, Koehn JA, Canfield RE, Landman SL, Friedman R. Development of a radioimmunoassay for the fibrinogen-derived peptide Bβ1-42. Blood 67:1014, 1986.
Koehn JA, Hurlet-Jensen A, Nossel HL, Canfield RE. Sequence of plasma proteolysis at the NH2-terminus of the Bβ chain of human fibrinogen. Anal Biochem 133:502, 1983.
Hurlet-Jensen A, Koehn JA, Nossel HL. The release of Bβ1-42 from fibrinogen and fibrin by plasmin. Thromb Res 29:609, 1983.
Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. Specificity of a monoclonal antibody for the NH2-terminal region of fibrin. Mol Immunol 21:89, 1984.
Eisenberg PR, Miletich JP. Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activacors in nonanticoagulated whole blood. Thromb Res 55:635, 1989.
Nieuwenhuizen W, Emers JJ, Vermond A. Catabolism of purified rat fibrin(ogen) plasma degradation products in rats. Thromb Haemost 48:59, 1982.
Lane DA, Ireland H, Knight I, Wolf S, Kyle P, Curtis JR. The significance of fibrinogen derivatives in plasma in human renal failure. Br J Haematol 56:251, 1984.
Walenga JM, Fareed J, Mariani G, Messmore HL, Bick RL, Emanuele RM. Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the Bβ15-42 sequence. Semin Thromb Haemost 10:252, 1984.
Eisenberg PR, Sherman LA, Jaffe AS. Differentiation of fibrinolysis from fibrinogenolysis with Bβ1-42 and Bβ15-42. Circulation 74:11–245, 1986.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Kluwer Academic Publishers
About this chapter
Cite this chapter
Lee, L.V., Abendschein, D.R., Eisenberg, P.R. (1997). Markers of Thrombosis and Fibrinolysis. In: Becker, R.C. (eds) Textbook of Coronary Thrombosis and Thrombolysis. Developments in Cardiovascular Medicine, vol 193. Springer, Boston, MA. https://doi.org/10.1007/978-0-585-33754-8_34
Download citation
DOI: https://doi.org/10.1007/978-0-585-33754-8_34
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-7923-9923-0
Online ISBN: 978-0-585-33754-8
eBook Packages: Springer Book Archive